Hair CML Chronic Myeloid Leukemia
Articles
Reversible skin and hair depigmentation during chemotherapy with dasatinib for chronic myeloid leukemia
January 2016, PublMed
Hypopigmentation of the Skin and Hair. Associated with Targeted Therapies
2014, Journal of Cancerology
New Drug (ruxolitinib) Helps Some Bald Patients Regrow Hair
August 17, 2014, The New York Times
Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
August 17, 2014, Nature.com
Hair depigmentation during chemotherapy with dasatinib, a dual Bcr-Abl/Src family tyrosine kinase inhibitor
April 8, 2009, NCBI
Cancer drug restores hair colour
August 8, 2002, BBC News
Imatinib Mesylate and Gray Hair
August 8, 2002, The New England Journal of médicine
Reversible skin and hair depigmentation during chemotherapy with dasatinib for chronic myeloid leukemia
January 2016, PublMed
Hypopigmentation of the Skin and Hair. Associated with Targeted Therapies
2014, Journal of Cancerology
New Drug (ruxolitinib) Helps Some Bald Patients Regrow Hair
August 17, 2014, The New York Times
Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
August 17, 2014, Nature.com
Hair depigmentation during chemotherapy with dasatinib, a dual Bcr-Abl/Src family tyrosine kinase inhibitor
April 8, 2009, NCBI
Cancer drug restores hair colour
August 8, 2002, BBC News
Imatinib Mesylate and Gray Hair
August 8, 2002, The New England Journal of médicine